Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer
nivolumabnivolumab-relatedGG5 PCaprostate cancer (PCa)HDRBTADTandrogen deprivation therapy
…ed immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients…